Elevance Health (ELV) Q1 2026 earnings review
A Low-Quality 'Beat' Masked by Non-Recurring Gains
Elevance Health raised its FY26 guidance and reported a Q1 Adjusted EPS beat of $12.58, but a look under the hood reveals a poor quality of earnings. The headline beat was heavily padded by ~$1.00 per share in non-recurring investment income. When stripped out, core earnings power actually declined YoY. Every single operating segment reported lower operating gains compared to a year ago, contradicting management's claim of 'underlying business strength.' Furthermore, GAAP earnings were crushed by a sudden $935 million accrual for a CMS Medicare Advantage risk adjustment probe, highlighting severe regulatory risk. While the company is successfully executing its strategy to shed unprofitable members and control administrative costs, the core medical insurance business remains under severe margin pressure.
🐂 Bull Case
Despite a tough medical cost environment, management raised FY26 Adjusted EPS guidance from 'at least $25.50' to 'at least $26.75,' signaling high visibility into second-half profitability.
Operating cash flow surged to $4.3 billion, an increase of $3.3 billion YoY, reversing the weak working capital dynamics seen at the start of 2025.
🐻 Bear Case
Segment Adjusted Operating Gain fell 1.6% YoY. The Adjusted EPS 'beat' was an illusion manufactured by a $1/share non-recurring investment gain and a lower share count.
A $935 million charge for historical CMS risk adjustments is a massive red flag. It wiped out over a third of the quarter's pre-tax income and raises questions about future Medicare Advantage billing scrutiny.
⚖️ Verdict: 🔴
Bearish. While Wall Street may applaud the raised guidance, the underlying financials show broad-based margin compression. A 'beat' built on one-off investment gains and share buybacks, combined with a nearly $1 billion regulatory hit, does not constitute a healthy quarter.
Key Themes
Management Narrative Contradicts the Data
CEO Gail Boudreaux stated that results 'exceeded expectations, reflecting underlying business strength.' The data tells the exact opposite story. Health Benefits operating gain fell 2.7%. CarelonRx operating gain fell 3.3%. Carelon Services operating gain fell 4.3%. Total Segment Adjusted Operating Gain fell 1.6%. There is no underlying operational strength driving this quarter's beat; it was engineered below the operating line via investment income.
Macro Regulatory Risk: The CMS Audit Bomb
Elevance recorded a $935 million accrual as its 'current best estimate' of potential exposure related to a February 2026 CMS notice regarding historical Medicare Advantage risk adjustment data. This is a severe macro-level regulatory risk. If CMS is retroactively clawing back nearly a billion dollars, it fundamentally alters the historical profitability profile of Elevance's MA book and signals a hostile regulatory environment going forward.
Margin Over Membership: The Culling Continues
Decelerating revenue growth is actually a positive sign here. As telegraphed in 2025, Elevance is intentionally shedding unprofitable members to reset its baseline. Medicare Advantage membership dropped 15.8% YoY (reversing from past growth cycles), and Medicaid dropped 4.6%. This disciplined volume reduction is necessary to fix the risk pool.
Carelon Services Top-Line Scaling
Carelon Services remains the primary growth engine for the top line. Operating revenue accelerated 12.7% YoY to $7.36 billion. The growth is driven by scaling risk-based solutions. However, profitability must catch up, as operating margins for the segment compressed from 7.5% to 6.4%.
Strict Operating Expense Discipline
With medical costs running hot (Benefit Expense Ratio up 40 bps to 86.8%), Elevance is pulling the only lever it fully controls: administrative costs. The adjusted operating expense ratio improved 20 basis points YoY to 10.5%. The company also took a $129 million business optimization charge to permanently streamline its organizational structure.
Clinical and Administrative Workflow Automation
To combat the relentless pressure of rising medical utilization, management is directing capital toward product and technology innovation. The company highlighted 'targeted investments across clinical, operational, and administrative workflows.' Building on prior rollouts of HealthOS and AI virtual assistants, this automation is critical to maintaining the 10.5% adjusted operating expense ratio.
Other KPIs
Decelerating profitability. Up 40 basis points YoY from 86.4%. Management cites expected elevated medical cost trends in the Medicaid business, which more than offset any improved performance in Medicare.
Stable/Improving liquidity metric. This represents an increase of 5.3 days sequentially and 3.8 days YoY. This dynamic contributed heavily to the massive $4.3 billion operating cash flow generation in the quarter.
Guidance
Accelerating vs prior estimates. This is an increase from the previous floor of '$25.50' provided at the end of 2025. However, it still represents a deceleration of roughly 11% compared to FY25's full-year print of ~$30.29, confirming that 2026 remains a 'trough year' for earnings.
Decelerating sharply. The massive gap between GAAP and Adjusted guidance (~$6.90 per share) is primarily driven by the $4.24 per share impact of the CMS risk adjustment accrual, alongside amortization and business optimization charges.
Stable. Reaffirmed from prior guidance. The $4.3 billion generated in Q1 significantly de-risks this annual target.
Key Questions
CMS Audit Exposure Scope
You recorded a massive $935 million accrual for historical CMS risk adjustments. Does this figure ring-fence the entirety of your exposure, or could ongoing CMS audits expand this liability to other payment years?
Contradiction in Core Profitability
Management highlighted 'underlying business strength,' yet all three reporting segments posted negative operating gain growth year-over-year. Excluding the $1 per share of non-recurring investment income, core earnings declined. What specific operational metrics give you the confidence to raise FY26 Adjusted EPS guidance?
Carelon Margin Compression
Carelon Services grew revenue nearly 13%, but operating margins compressed by 110 basis points to 6.4%. Is this margin deterioration a temporary result of scaling new risk-based clients, or a structural reality of the current pricing environment?